Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombotic therapy during pregnancy.

W S Chan1, S D Chunilal, A S Ginsberg

  • 1Department of Medicine, Women's College Campus, Sunnybrooke and Women's College Health Sciences Centre, Toronto, Ontario, Canada.

Seminars in Perinatology
|July 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Descriptive analysis of platelet-rich plasma injection therapy in chronic musculoskeletal pain.

Hong Kong medical journal = Xianggang yi xue za zhi·2026
Same author

Observation of Single-Top-Quark Production in Association with a Photon Using the ATLAS Detector.

Physical review letters·2023
Same author

Observation of the γγ→ττ Process in Pb+Pb Collisions and Constraints on the τ-Lepton Anomalous Magnetic Moment with the ATLAS Detector.

Physical review letters·2023
Same author

Strong Constraints on Jet Quenching in Centrality-Dependent p+Pb Collisions at 5.02 TeV from ATLAS.

Physical review letters·2023
Same author

Search for Heavy Neutral Leptons in Decays of W Bosons Using a Dilepton Displaced Vertex in sqrt[s]=13  TeV pp Collisions with the ATLAS Detector.

Physical review letters·2023
Same author

Observation of WWW Production in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2022

Antithrombotic therapy in pregnancy requires careful anticoagulant selection. Current dosing for unfractionated heparin and low molecular weight heparin in pregnant women needs further investigation due to physiological changes.

Area of Science:

  • Obstetrics and Gynecology
  • Hematology
  • Pharmacology

Background:

  • Antithrombotic therapy is crucial during pregnancy for managing thromboembolism and preventing pregnancy loss.
  • Warfarin is contraindicated, limiting anticoagulant choices to unfractionated heparin (UFH) and low molecular weight heparin (LMWH).

Purpose of the Study:

  • To evaluate the appropriateness of current UFH and LMWH dosing in pregnant women.
  • To address uncertainties in anticoagulant pharmacokinetics and efficacy during pregnancy.

Main Methods:

  • Review of existing literature on UFH and LMWH use in pregnancy.
  • Analysis of physiological changes during pregnancy impacting drug pharmacokinetics.
  • Assessment of monitoring methods for UFH in pregnant patients.

Related Experiment Videos

Main Results:

  • Pharmacokinetic and dosing data from non-pregnant populations may not be directly applicable to pregnant women.
  • Activated partial prothrombin time (aPTT) reliability for UFH monitoring in pregnancy is questionable.
  • Optimal LMWH dosing strategies in pregnancy remain uncertain.

Conclusions:

  • Significant physiological alterations in pregnancy necessitate a re-evaluation of anticoagulant dosing.
  • Further research is required to establish safe and effective UFH and LMWH dosing regimens for pregnant patients.
  • Accurate dosing is critical to mitigate maternal morbidity and mortality associated with venous thromboembolism.